Brief: Calidi Biotherapeutics Receives FDA Fast Track Designation For Cld-201 (Supernova), A First-In-Class Stem-Cell Loaded Viral Therapy For The Treatment Of Patients With Soft Tissue Sarcoma
29/07/2025 14:33
July 29 (Reuters) - Calidi Biotherapeutics Inc CLDI.A: CALIDI BIOTHERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR CLD-201 (SUPERNOVA), A FIRST-IN-CLASS STEM-CELL LOADED VIRAL THERAPY FOR THE TREATMENT OF PATIENTS WITH SOFT TISSUE SARCOMA Source text: ID:nGNXbMgJhk Further company coverage: CLDI.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calidi Biotherapeutics
See all newsBrief: Calidi Biotherapeutics Announces Strategic Partnership With Transferai
Brief: Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval
Brief: Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public Offering
Brief: Calidi Biotherapeutics Eliminates Chief Legal Officer Position - SEC Filing
Brief: Calidi Biotherapeutics Receives FDA Fast Track Designation For Cld-201 (Supernova), A First-In-Class Stem-Cell Loaded Viral Therapy For The Treatment Of Patients With Soft Tissue Sarcoma